Notably, the UK/ANZ [18] and NSABP B-24 [19] trials were conducted before the routine evaluation of hormone receptor status in DCIS, whereas the TAM-01 trial [20] only included ER-positive (or unknown status) DCIS. The gene discussed is NR4A1; the disease is ductal breast carcinoma in situ.